Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract

Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. In the phase 3 EMPOWUR trial, vibegron significantly reduced the average daily number of micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes vs placebo. This analysis assessed the meaningfulness of reductions in clinical endpoints observed in EMPOWUR using the patient's perception of improvement.


Jeffrey Frankel, MD, Urologist, Medical Director, Seattle Urology Research Center, Seattle, WA

Diane K. Newman, DNP, ANP-BC, FAAN, Adjunct Professor of Urology in Surgery, Perelman School of Medicine, University of Pennsylvania, and former Co-Director of the Penn Center for Continence and Pelvic Health.

Read the Abstract